Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
31.05
+3.94 (14.53%)
At close: Aug 19, 2026, 4:00 PM EDT
32.00
+0.95 (3.06%)
After-hours: Aug 19, 2026, 6:55 PM EDT
Scribe Therapeutics Revenue
Scribe Therapeutics had revenue of $2.23M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $36.28M. In the year 2025, Scribe Therapeutics had annual revenue of $51.17M with 86.68% growth.
Revenue (ttm)
$36.28M
Revenue Growth
+86.68%
P/S Ratio
16.14
Revenue / Employee
$407,663
Employees
89
Market Cap
585.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.17M | 23.76M | 86.68% |
| Dec 31, 2024 | 27.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
SCTX News
- 1 day ago - Leerink starts Scribe Therapeutics at Outperform on X-editor platform - TheFly
- 1 day ago - Scribe Therapeutics initiated with an Outperform at Leerink - TheFly
- 1 day ago - Scribe Therapeutics initiated with a Buy at Guggenheim - TheFly
- 1 day ago - Scribe Therapeutics initiated with an Overweight at Wells Fargo - TheFly
- 1 day ago - Scribe Therapeutics initiated with Early-Stage Biotech at Goldman Sachs - TheFly
- 23 days ago - Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement - GlobeNewsWire
- 23 days ago - Opening Day: Scribe Therapeutics makes strong trading debut - TheFly
- 26 days ago - Scribe Therapeutics opens at $25, IPO priced at $15 per share - TheFly